Decorative image

Screening

There isn’t a national screening programme for primary liver cancer (cancer that started in the liver) in the UK. You might have regular checks if you are at high risk of developing it. 

What is screening?

Screening means testing people for early stages of a disease before they have any symptoms. For screening to be useful the tests:

  • need to be reliable at picking up cancers
  • overall must do more good than harm to people taking part
  • must be something that people are willing to do

Screening tests are not perfect and have some risks. The screening programme should also be good value for money for the NHS.

No screening available

There is no screening programme for liver cancer in the UK because:

  • it's rare so we wouldn't find many cancers
  • there's no suitable test to use for liver cancer screening
  • the cost of screening would be high

Testing for people at high risk

For any rare or uncommon cancer, it is most cost effective to screen people who are thought to be at higher risk.

There are some groups of people that doctors already know are at higher risk of primary liver cancer (hepatocellular cancer or HCC).

Your doctor might recommend routine testing if you have:

  • scarring of your liver (liver cirrhosis)
  • long term (chronic) infection of hepatitis B or C infection
  • non alcoholic fatty liver disease

If you are at higher risk, you usually have an ultrasound scan every 6 months to check for growths in your liver. You may also have blood tests for AFP (alpha fetoprotein), which can be raised in some people with HCC.

Having these tests regularly can pick up hepatocellular cancers earlier, when they are smaller and surgery may be possible. 

Speak to your liver specialist at your next check up if you have cirrhosis and are concerned that you're not having tests. They usually suggest tests if you are well enough for  treatment, should you have liver cancer.

Last reviewed: 
20 Mar 2018
  • Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up
    A Vogel and others
    Annals of Oncology, 2018. Volume 29, Supplement 4, Pages 238-255

  • EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
    European Association for the Study of the Liver
    Journal of Hepatology, 2018. Volume 69, Pages 182-236

Information and help

Dangoor sponsorship

About Cancer generously supported by Dangoor Education since 2010.